XOMA Corporation Культура компании

Mr. Thomas Burns, also known as Tom, has been the Chief Financial Officer of XOMA Corporation since April 3, 2015 and has been its Senior Vice President of Finance since May 24, 2017. Mr. Burns served as Vice President of Finance at XOMA Corporation since April 2015 until May 24, 2017. He joined the XOMA finance team in 2006 and has been an essential member in its financing and financial reporting activities. Prior to XOMA, he held multiple senior financial management positions at high-tech companies including Mattson Technology, IntruVert Networks (acquired by McAfee), Niku Corporation (acquired by Computer Associates) and Conner Technology. Mr. Burns received his Bachelor's degree from Santa Clara University and his Masters of Business Administration from Golden Gate University.

Dr. Deepshikha Datta, also known as Dee, has been Chief Business Officer of XOMA Corp. since December 2017. Dr. Datta joined XOMA from Forty Seven Inc. As the Vice President of Corporate Development at Forty Seven, Dr. Datta managed business development, strategy and transactions, company financing, and investor relations. Dr. Datta joined Forty Seven from XOMA where she was the Senior Director of Business Development. During her time at XOMA, she successfully closed multiple transactions including licensing deals with large pharmaceutical companies, such as Novartis and Novo Nordisk. Dr. Datta was a Principal at The Column Group LLC. She joined the firm in January 2010. Dr. Datta has more than 12 years of experience in biomedical research, biotechnology startups, venture capital, business development and investment banking. Most recently, she was a Consultant at TPG Biotech where she evaluated early stage investments as well as large structured financing deals. Prior to that, Dr. Datta was at DE Shaw & Co. where she was responsible for business development activities for an internal biotech investment. She has also worked at Healthcare Investment Banking Group at JP Morgan, where she focused on mergers and acquisitions for biotechnology clients. She co-founded Allozyne, Inc. and served as its Vice President and Member of Scientific Advisory Board. Dr. Datta helped to develop the Allozyne, based on technologies licensed from California Institute of Technology (Caltech). She earned Ph.D. degree in Biochemistry and Molecular Biophysics from California Institute of Technology and an M.B.A. from the Stanford Graduate School of Business.

Dr. Paul D. Rubin, M.D., has been Executive Vice President of Research and Development at miRagen Therapeutics, Inc. since November 29, 2016. Dr. Rubin served as the Chief Medical Officer at XOMA Corporation from June 2011 to November 18, 2016 and served as its Senior Vice President of Research & Development from April 24, 2012 to November 18, 2016. Mr. Rubin served as an Executive Vice President of Development at Sunovion Pharmaceuticals Inc. Mr. Rubin served as Vice President of Clinical Development at XOMA Corporation. Dr. Rubin served as President and Chief Executive Officer of Resolvyx Pharmaceuticals Inc. from 2007 to 2009. Dr. Rubin Joined Resolvyx Pharmaceuticals, Inc. in January 2007. Dr. Rubin served as Chief Medical Officer at Funxional Therapeutics Ltd. He served as the President and Chief Executive Officer of Critical Therapeutics, Inc. from August 2002 to June 26, 2006. Dr. Rubin served as Executive Vice President of Research and Development for Sepracor Inc., from April 1996 to August 2002. Dr. Rubin served as Vice President and Worldwide Director Early Clinical Development & Clinical Pharmacology of GlaxoWellcome Inc. from July 1993 to March 1996. Dr. Rubin served as Vice President of Immunology and Endocrine Development for Abbott Laboratories from June 1987 to June 1993. he led the development of Sepracor's internally developed approved products including Xopenex, Lunesta, Xopenex HFA and Brovana. From 1993 to 1996, Dr. Rubin held senior level positions at Glaxo-Wellcome Pharmaceuticals, including Vice President of Worldwide Clinical Pharmacology and Early Clinical Development. From 1987 to 1993, Dr. Rubin held various roles with Abbott Laboratories, including as Vice President, Immunology and Endocrinology, where he successfully advanced zileuton, the first 5-lipoxygenase inhibitor, from discovery to approval for the treatment of asthma. He served as Director of Soligenix, Inc. since November 1997. He served as a Director of Resolvyx Pharmaceuticals, Inc. He also served as a Director of Critical Therapeutics Inc. from October 2002 to June 26, 2006. He holds a B.A. in Biology from Occidental College. Dr. Rubin received his M.D. from Rush Medical College in Chicago and completed his residency in Internal Medicine at the University of Wisconsin Hospitals and clinics in Madison, Wisconsin.